Literature DB >> 15337976

Halo nevus, rather than vitiligo, is a typical dermatologic finding of turner's syndrome: clinical, genetic, and immunogenetic study in 72 patients.

Valeria Brazzelli1, Daniela Larizza, Miriam Martinetti, Sara Martinoli, Valeria Calcaterra, Annalisa De Silvestri, Roberta Pandolfi, Giovanni Borroni.   

Abstract

Turner's syndrome (TS) is a genetic disorder caused by numeric and/or structural abnormalities of the X chromosome; it is characterized by short stature, gonadal dysgenesis, and frequently by webbed neck, cubitus valgus, and lymphedema at birth. TS has been associated with several cutaneous abnormalities including an increased frequency of pigmented nevi, but few reports consider nevi in detail. Halo nevus (HN) is clinically defined as a melanocytic nevus surrounded by a halo of depigmentation. Vitiligo, a dermatologic disorder characterized by the presence of depigmented patches on the skin, has been described in the list of cutaneous findings associated with TS. The aim of this study was to determine the prevalence of HN and vitiligo in TS and to evaluate if a correlation between major histocompatibility complex genes, karyotype, autoimmunity, therapies, and the presence of HN exists. Of the 72 patients with TS examined, 13 had HN, a prevalence of 18.05%, which was significantly higher than in our control group (1%; P=.000001). On the contrary, only 2 patients with TS (2.77%, P=not significant) had vitiligo. By comparing the distribution of HLA class I alleles between patients with TS who did (13 of 72) and did not (59 of 72) have HN, we observed a significantly higher frequency of HLA-Cw6 in patients with TS and HN than in those without HN (26.92% vs 6.78%, respectively; P=.0067; odds ratio=5.06). The study of HLA class II genomic polymorphisms showed that the DRB1(*)0701 and DQB1*02 alleles for patients with TS and HN were overrepresented when compared with those without HN (34.61% vs 11.86%, respectively, P=.0078, odds ratio=3.93; and 34.61% vs 19.49%, respectively, P=.1386, odds ratio=2.19). In conclusion, this study is the first to demonstrate an increased prevalence of HN for patients with TS. Furthermore, the data suggest that a HN putative susceptibility gene in TS is located close to the HLA-C locus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337976     DOI: 10.1016/j.jaad.2003.11.082

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol).

Authors:  Elodie Fiot; Bertille Alauze; Bruno Donadille; Dinane Samara-Boustani; Muriel Houang; Gianpaolo De Filippo; Anne Bachelot; Clemence Delcour; Constance Beyler; Emilie Bois; Emmanuelle Bourrat; Emmanuel Bui Quoc; Nathalie Bourcigaux; Catherine Chaussain; Ariel Cohen; Martine Cohen-Solal; Sabrina Da Costa; Claire Dossier; Stephane Ederhy; Monique Elmaleh; Laurence Iserin; Hélène Lengliné; Armelle Poujol-Robert; Dominique Roulot; Jerome Viala; Frederique Albarel; Elise Bismuth; Valérie Bernard; Claire Bouvattier; Aude Brac; Patricia Bretones; Nathalie Chabbert-Buffet; Philippe Chanson; Regis Coutant; Marguerite de Warren; Béatrice Demaret; Lise Duranteau; Florence Eustache; Lydie Gautheret; Georges Gelwane; Claire Gourbesville; Mickaël Grynberg; Karinne Gueniche; Carina Jorgensen; Veronique Kerlan; Charlotte Lebrun; Christine Lefevre; Françoise Lorenzini; Sylvie Manouvrier; Catherine Pienkowski; Rachel Reynaud; Yves Reznik; Jean-Pierre Siffroi; Anne-Claude Tabet; Maithé Tauber; Vanessa Vautier; Igor Tauveron; Sebastien Wambre; Delphine Zenaty; Irène Netchine; Michel Polak; Philippe Touraine; Jean-Claude Carel; Sophie Christin-Maitre; Juliane Léger
Journal:  Orphanet J Rare Dis       Date:  2022-07-12       Impact factor: 4.303

2.  A Case of Alopecia Areata in a Patient with Turner Syndrome.

Authors:  Serena Gianfaldoni; Georgi Tchernev; Uwe Wollina; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2017-07-23

3.  Autoimmunity Predisposition in Girls With Turner Syndrome.

Authors:  Malgorzata Wegiel; Aleksandra Antosz; Joanna Gieburowska; Kamila Szeliga; Magdalena Hankus; Urszula Grzybowska-Chlebowczyk; Sabina Wiecek; Ewa Malecka-Tendera; Aneta Gawlik
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-30       Impact factor: 5.555

4.  Associated clinical abnormalities among patients with Turner syndrome.

Authors:  Suna Kilinc; Metin Yildiz; Ayla Guven
Journal:  North Clin Istanb       Date:  2020-04-14

5.  Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study.

Authors:  M Cappa; L Iughetti; S Loche; M Maghnie; A Vottero
Journal:  J Endocrinol Invest       Date:  2015-12-28       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.